#Canada #Toronto #Cardiol Therapeutics #CardiolRx #MAVERIC Program

Cardiol Therapeutics to Host Virtual AGM

Cardiol Therapeutics Inc. is gearing up for an important event as it announces its Annual General Meeting (AGM) of shareholders set for June 24, 2026, at 4:30 PM EDT. This meeting marks a key occasion for investors and shareholders to engage with the company's current developments and future trajectory.

Cardiol Therapeutics, listed on NASDAQ and TSX under CRDL, is a late-stage life sciences company principally focused on developing innovative treatments for heart diseases, particularly through anti-inflammatory and anti-fibrotic therapies. These developments are especially significant in light of rising heart disease cases globally.

The Focus of the AGM

This year's AGM will be a virtual event, streamed live, allowing shareholders to participate from the comfort of their own homes or offices. Attendees can access the meeting via the following link: Cardiol AGM Webcast. As the company positions itself for future growth, details regarding participation and voting procedures are accessible on the official website: cardiolrx.com/investors/events-presentations/.

Key Developments at Cardiol Therapeutics

A significant highlight of Cardiol's agenda is its flagship product, CardiolRx™, which is designed to modulate the inflammasome pathway—a critical process in the inflammation and fibrosis related to heart diseases, including pericarditis, myocarditis, and heart failure. The drug has garnered attention not only for its innovative approach but also because it has been granted Orphan Drug Designation by the U.S. FDA for treating recurrent pericarditis.

The company is actively conducting trials under its specialized MAVERIC Program aimed at addressing recurrent pericarditis, a serious condition that affects patients with recurring chest pain and breathing difficulties. The ongoing Phase III MAVERIC trial has generated considerable interest, especially since the condition poses risks that can severely impact quality of life.

In addition, Cardiol is pushing forward with its ARCHER Program, which evaluates CardiolRx™ in patients suffering from acute myocarditis—a condition that disproportionately affects younger adults and can lead to sudden cardiac death. A completed Phase II study has set the stage for further exploration of this drug's potential benefits.

Besides CardiolRx™, the company is also advancing CRD-38, a novel subcutaneously injectable drug formulation aimed at treating inflammatory heart diseases. Given that heart failure remains a leading cause of hospitalization and mortality, particularly in developed nations, the implications of these developments could prove transformative.

Forward-Looking Statements

While the AGM promises to be filled with insights and exciting news about Cardiol Therapeutics' pipeline, attendees are reminded that the discussions may contain forward-looking information, subject to a variety of risks and uncertainties. The company's future performance is based on numerous factors that investors should consider carefully.

As Cardiol Therapeutics continues to pave the way in providing innovative solutions for heart disease, stakeholders eagerly await the AGM for updates on the company's progress and future direction. For continuous updates and information, interested parties are encouraged to visit the company’s official website.

In conclusion, the upcoming AGM represents not just a moment of accountability for Cardiol Therapeutics but also an opportunity for shareholders and interested audiences to connect and understand the company's pivotal role in combating heart diseases.

For more information, please visit: cardiolrx.com